Diplomat CEO receives award from Ernst & Young
SWARTZ CREEK, Mich. Diplomat Specialty Pharmacy on Friday announced Diplomat president and CEO Phil Hagerman was named Ernst & Young Entrepreneur of the Year for the Michigan and northwest Ohio region.
Hagerman received the award on June 10 at an awards ceremony at the Ritz Carlton Hotel in Dearborn, Mich. The Ernst & Young Entrepreneur of the Year is one of the world’s most prestigious business awards for entrepreneurs, and honors outstanding entrepreneurs who inspire others with their vision, leadership and achievement. As the Michigan/northwest Ohio winner in the retail and services category, Hagerman now is a candidate for the National Entrepreneur of the Year award, which will be announced at the annual Ernst & Young awards event in November 2010 in Palm Springs, Calif.
The news comes soon after Diplomat announced it would move its headquarters to Flint’s Great Lakes Technology Centre from nearby Flint Township as part of a large expansion of the company.
MannKind: Afrezza works just as effectively as competing diabetes drugs in trial
VALENCIA, Calif. An investigational insulin made by MannKind works at least as well in patients with Type 1 diabetes as the standard therapy, MannKind said Thursday.
The drug maker said a 16-week clinical trial showed that the fast-acting inhaled mealtime insulin Afrezza (insulin human [rDNA origin]) combined with basal insulin worked as well as Eli Lilly’s injectable Humalog (insulin lispro [rDNA origin]). In addition, MannKind said, patients taking Afrezza showed lower rates of hypoglycemia – or low blood sugar – in after-meal and fasting blood glucose levels than those taking Humalog.
“Effectively controlling blood sugar levels and managing hypoglycemic events go hand in hand as key to successfully treating patients with Type 1 diabetes,” lead study investigator and University of Colorado medical professor Satish Garg said. “Our findings demonstrate that Afrezza may offer a significant advance from current mealtime insulin delivery methods, as it is comparable to the standard of care in glycemic control and provides the additional benefit of lower hypoglycemia rates.”
Bayer HealthCare: Betaferon’s safety record proven in follow-up trial
BERLIN German drug maker Bayer HealthCare said a 16-year follow-up to a clinical trial of one of its multiple sclerosis drugs supported the drug’s safety record.
Bayer said results of the follow-up study for Betaferon (interferon-beta-1b), published Tuesday in the journal Neurology, revealed no new or unexpected harmful side effects emerging with long-term therapy, while observed side effects related to the drug decreased over time. The drug is marketed in the United States and Canada as Betaseron.
“These data confirm that Betaferon has a favorable safety and tolerability profile,” lead study author and University of Chicago neurology professor Anthony Reder said. “Over the years, healthcare professionals have been able to greatly reduce treatment-related adverse events and increase patients’ adherence to Betaferon therapy with dose escalation at initiation of therapy and the routine use of an autoinjector and co-medication with nonsteroidal anti-inflammatory drugs.”